Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.69 |
| ▸ | NPY4R | P50391 | 8/20 | 0.69 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.69 |
| ▸ | NPY1R | P25929 | 6/20 | 0.69 |
| ▸ | TFPI | P10646 | 7/20 | 0.67 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.65 |
| ▸ | CALCR | P30988 | 3/20 | 0.65 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.58 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apidaecin SCHEMBL29380656 | 0.90 | NPY4R (0.67) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29360416 | 0.89 | NPY2R (0.66) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| Apidaecin Ia SCHEMBL29458103 | 0.88 | NPY2R (0.63) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29458102 | 0.87 | NPY4R (0.62) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| Isracidin SCHEMBL29668326 | 0.85 | NPY2R (0.70) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL32930844 | 0.85 | AGTR1 (0.70) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29509548 | 0.84 | TFPI (0.65) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| Talfirastide SCHEMBL29367137 | 0.84 | AGTR2 (0.73) | NPY2RNPY4RNPY5RNPY1RAGTR1 | |
| SCHEMBL29359777 | 0.84 | NPY2R (0.63) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30495738 | 0.84 | NPY2R (0.61) | NPY2RNPY4RNPY5RNPY1RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097149-A1 | CELL FREE VASCULAR GRAFTS AND GRAFT MATERIALS FOR CELLULAR RECRUITMENT | UNIV NEW YORK STATE RES FOUND (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260055150-A1 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | UNIV MICHIGAN (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4565333-A2 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | Regents of the University of Michigan (US) | 2025-06-11 | — | — | EP | disclosed |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| CN-119019369-A | Bifunctional molecules comprising an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20240325547-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| CN-115397821-B | Bifunctional molecules comprising an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-118388454-A | Modulators of BCL6 proteolysis and related methods of use | 阿尔维纳斯运营股份有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-110520729-B | Methods for generating and screening isolated peptide libraries | 南安普顿大学 | 2024-05-28 | — | — | CN | disclosed |
| US-11986532-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-117717617-A | Amphiphilic polyoxazoline vaccine carrier, preparation method and application thereof | 中国科学院长春应用化学研究所 | 2024-03-19 | — | — | CN | disclosed |
| EP-4323352-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2024031003-A2 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024026035-A2 | PEPTIDE TAGS FOR PHAGE IMAGING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023250519-A1 | CELL FREE VASCULAR GRAFTS AND GRAFT MATERIALS FOR CELLULAR RECRUITMENT | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220323457-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-4045496-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | Arvinas Operations, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055150-A1 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | TP53, TP53BP1, DDIT3 | NPY2R 1365/4885NPY4R 1094/4885NPY5R 1544/4885 |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | NPY2R 4228/4885NPY4R 4527/4885NPY5R 4568/4885 |
| US-11986532-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | NPY2R 4201/4885NPY4R 4154/4885NPY5R 4185/4885 |
| US-20220323457-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | NPY2R 4228/4885NPY4R 4527/4885NPY5R 4568/4885 |
| US-20260097149-A1 | CELL FREE VASCULAR GRAFTS AND GRAFT MATERIALS FOR CELLULAR RECRUITMENT | HCLS1, ADM2, LY96 | NPY2R 3284/4885NPY4R 3845/4885NPY5R 3576/4885 |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | NPY2R 4201/4885NPY4R 4154/4885NPY5R 4185/4885 |
| US-20240325547-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | NPY2R 4201/4885NPY4R 4154/4885NPY5R 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.